Results 1 to 10 of about 4,852 (207)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide [PDF]

Drugs in Context, 2021
Although tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have been evaluated in various clinical trials, limited safety and efficacy data exist in real-world settings.
Sarah M Michienzi, Mikayla Johnson, Thomas D Chiampas, Eric Wenzler, Rodrigo M Burgos, Renata O Smith, Melissa E Badowski   +6 more
doaj   +5 more sources

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients [PDF]

Infection and Drug Resistance, 2023
Jingjing He, Yifei Guo, Yao Zhang, Jiajia Han, Jingwen Chen, Yidi Jia, Zhenxuan Ma, Jingwen Wu, Shenyan Zhang, Fahong Li, Richeng Mao, Jiming Zhang Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency ...
He J, Guo Y, Zhang Y, Han J, Chen J, Jia Y, Ma Z, Wu J, Zhang S, Li F, Mao R, Zhang J   +11 more
doaj   +4 more sources

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate [PDF]

Drugs in R&D
Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus.
Derek E. Murrell, Benjamin C. Kennard, Maria E. Bertoni, David B. Cluck, Jonathan P. Moorman, Stacy D. Brown, Kesheng Wang, Michelle M. Duffourc, Sam Harirforoosh   +8 more
doaj   +3 more sources

Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations [PDF]

Pharmacogenomics and Personalized Medicine, 2021
Xue Li,1,* Xin-Yi Tan,2,* Xue-Jun Cui,3 Ming Yang,1 Chao Chen,1 Xiao-Yun Chen2 1Phase I Clinical Research Laboratory of Shanghai LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China ...
Li X, Tan XY, Cui XJ, Yang M, Chen C, Chen XY   +5 more
doaj   +4 more sources

Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B [PDF]

Frontiers in Medicine, 2022
BackgroundTenofovir alafenamide fumarate has been used in late pregnancy; however, no data exist regarding its safety and effectiveness in early and middle pregnancy for mothers with hepatitis B virus infection.AimsTo design a prospective study to ...
Ruochan Chen, Ruochan Chen, Ju Zou, Ju Zou, Liyuan Long, Liyuan Long, Haiyue Huang, Min Zhang, Min Zhang, Xuegong Fan, Xuegong Fan, Yan Huang, Yan Huang, Yan Huang   +13 more
doaj   +2 more sources

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study [PDF]

AIDS Research and Therapy, 2021
Background Antiretrovirals, including tenofovir, can suppress human immunodeficiency virus (HIV) infection but cannot completely eradicate it. Patients with HIV infection are administered antiretroviral drugs over a long term; thus, managing consequent ...
Mahoko Ikeda, Yoshitaka Wakabayashi, Koh Okamoto, Shintaro Yanagimoto, Shu Okugawa, Kyoji Moriya   +5 more
doaj   +2 more sources

Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study [PDF]

AIDS Research and Therapy, 2021
Background Tenofovir disoproxil fumarate (TDF) has a strong antiviral effect, but TDF is known to cause renal dysfunction. Therefore, we are investigating preventing renal dysfunction by replacing TDF with tenofovir alafenamide fumarate (TAF), which is ...
Kensuke Abe, Taku Obara, Satomi Kamio, Asahi Kondo, Junji Imamura, Tatsuya Goto, Toshihiro Ito, Hiroshi Sato, Nobuyuki Takahashi   +8 more
doaj   +2 more sources

Improvement in kidney function in patients with chronic hepatitis B and chronic kidney disease after switching to tenofovir alafenamide fumarate: a systematic review with single arm meta-analysis [PDF]

Brazilian Journal of Nephrology
Introduction: Tenofovir disoproxil fumarate (TDF) is effective in treating hepatitis B virus, (HBV) but has been associated with nephrotoxicity. In contrast, tenofovir alafenamide fumarate (TAF) has emerged as a safer alternative, reducing kidney ...
João Galdino de Pascoa Junior, Ramon Huntermann, Victor Machado Viana Gomes, Frederico de Sousa Marinho Mendes Filho, João Marcelo Vallim Bertozzi, Paulo Ricardo Gessolo Lins   +5 more
doaj   +2 more sources

Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study [PDF]

Journal of Pharmaceutical Health Care and Sciences
Background Continued use of tenofovir disoproxil fumarate (TDF), an antiretroviral drug, causes renal function decline and tubular damage in individuals with HIV. While tenofovir alafenamide fumarate (TAF) may have less damaging effects, it causes weight
Kensuke Abe, Junji Imamura, Akiko Sasaki, Tomoko Suzuki, Satomi Kamio, Taku Obara, Toshihiro Ito   +6 more
doaj   +2 more sources

1551. Changes in Glomerular Filtration Rate after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis [PDF]

Open Forum Infect Dis, 2023
Adovich S. Rivera, Matthew T. Mefford, Katherine J Pak, Rulin C. Hechter   +3 more
europepmc   +2 more sources